National Institutes of Health (NIH)
Funding Opportunity Title
Competitive Revision Applications for Research on Neural Processes Underlying Sex Differences Related to Risk and Resilience for Mental Illness (R01)
R01 Research Project Grant
Funding Opportunity Announcement (FOA) Number
Catalog of Federal Domestic Assistance (CFDA) Number(s)
This Funding Opportunity Announcement (FOA) seeks to support basic and translational research on the neurobiology of sex differences. Specifically, NIMH and ORWH solicit revision applications (formerly called competitive supplement applications) that explicitly test hypotheses regarding neural mechanisms underlying sex differences relevant to mental health. Applications should articulate a strong rationale for how the proposed project will significantly advance our understanding of the etiology and/or underlying pathophysiology of mental disorders in males and females.
This FOA is limited to revision applications to currently active NIMH-supported R01 grants. Revision applications will provide funds for 1) recruiting additional subjects to provide enough power to address hypotheses about sex differences or 2) thorough analyses of pre-existing data where sex specific analyses were not initially included, and power is sufficient.
December 13, 2011
Open Date (Earliest Submission Date)
February 13, 2012
Letter of Intent Due Date
February 13, 2012
Application Due Date(s)
March 13, 2012, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)
Scientific Merit Review
Advisory Council Review
Earliest Start Date(s)
March 14, 2012
Due Dates for E.O. 12372
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
This Funding Opportunity Announcement (FOA) issued by the National Institute of Mental Health (NIMH) and the Office of Research on Women's Health (ORWH), National Institutes of Health, seeks to support basic and translational research on the neurobiology of sex differences. Specifically, NIMH is encouraging revision applications to augment currently active NIMH R01 grants. Revision applications should explicitly test hypotheses regarding neural mechanisms underlying sex differences relevant to mental health. Applications should articulate a strong rationale for how the proposed project will significantly advance our understanding of the etiology and/or underlying pathophysiology of mental disorders in males and females.
Research supported by this initiative will aim to understand how interactions between sex chromosomes, steroid hormones and environment shape sexually dimorphic neural pathways and behavior. Research projects funded under this FOA will aim to advance our understanding of how sexual dimorphisms influence clinical symptoms and age of onset of mental disorders. Periods of developmental divergence between the sexes, periods of rapid developmental change, and periods during which environmental influences are particularly strong present an opportunity for understanding sex-specific neurodevelopmental trajectories. As a result, studies testing developmental questions are strongly encouraged under this funding opportunity. Genetic variants with known associations to mental illness offer an opportunity to explore how genetic risk is linked to changes in brain function and circuitry. Sex differences in the prevalence and symptom profiles of mental disorders suggest sex differences in genetic risk. Therefore, studies investigating sex differences in genotype association or gene expression are encouraged under this funding opportunity. Applications investigating sex-specific gene associations in existing samples would be appropriate for this FOA, if the proposed questions were not part of the original planned analyses or specific aims of the parent study. Revision applications may focus exclusively on one sex if the intent is to supplement parent projects in which the chosen sex was under-represented or excluded, with the provision that the additional subjects must provide sufficient statistical power to test specific aims regarding sex differences.
The NIMH has defined four overarching objectives in a Strategic Plan designed to carry out our mission of transforming the understanding and treatment of mental illnesses through basic and clinical research. Two Strategic Objectives are directly addressed by this FOA. The first, to promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders, is met through basic, translational and clinical research that investigates genetic, neurobiological, behavioral, environmental and experiential factors in the etiology of disorders. The second objective focuses on understanding where, when and how to intervene by charting the trajectories of mental disorders over the lifespan in an effort to identify appropriate points of intervention to hasten recovery or prevent onset of illness.
An individual’s sex can influence susceptibility, prevalence, and age of onset for psychiatric disorders. Disorders that emerge early in development, such as autism, ADHD, Tourette Syndrome, and early-onset schizophrenia, tend to be more prevalent in males. Disorders with onset in adolescence or adulthood, such as major depression, anxiety disorders, and eating disorders, are more prevalent in females. Despite these clear epidemiological trends, very little is known about the precise timing, neural circuitry, or mechanisms underlying the expression of sex differences in mental disorders.
Sex differences have been largely overlooked in many research studies because of prevailing practices and biases in the field (Cahill, 2010; Nature, 2010; Office of Research on Women’s Health, 2010). Sex is often not considered in analyses, frequently due to a lack of power to address this question. Animal research studies frequently include only one sex in their experimental designs. Also lacking are theoretical models of disease that attempt to explain how neurobiological sex differences interact with other biological or environmental factors to confer risk and resilience for mental disorders. Moreover, because sex differences may be one factor underlying individual differences in response to treatments and interventions, research on sex differences related to the etiology of mental disorders may provide information fundamental to the development of personalized interventions.
Sex differences are often driven by organizational effects during early brain development or activational effects related to variation in circulating hormone levels. A significant area of research concerns the precise timing of sex-specific genetic, epigenetic, and hormonal events during neurodevelopment. This FOA encourages applications that focus on interactions between such events and the resulting long-lasting sexual dimorphisms in cognitive, affective or social function. Research using animal and/or human subjects is encouraged.
One major objective of this initiative is to encourage researchers who have not previously focused on sex differences to include sex as a factor in their designs and analyses. Another major goal is to stimulate the development of conceptual frameworks that hypothesize how sex influences risk for mental illness. It is expected that findings from these investigations will enhance our ability to predict, diagnose, and intervene in mental disorders. Because the intent of this FOA is to foster new approaches emphasizing neuronal mechanisms rather than existing lines of investigation, the FOA emphasizes exploratory, high-risk, and potentially groundbreaking studies.
Examples of research topics include, but are not limited to, the following:
The description of the research project should include concrete indicators of progress and how these indicators will be used to inform the next phase of research on sex differences in mental health. Appropriate indicators may include, but are not limited to, recruitment schedules, interim data analyses, and/or a timeline for administrative and scientific accomplishments. Progress indicators should be included in each annual progress report and as part of the final report for the grant.
Responsive applications must include both males and females, or provide evidence that exclusive focus on one sex is justified because the chosen sex was under-represented or excluded in the parent grant and the additional subjects will provide sufficient statistical power to test specific aims regarding sex differences. Specific aims must explicitly test hypotheses regarding sex differences. Hypotheses must address neural mechanisms and not focus solely on behavioral or epidemiological outcomes. Relevant applications must consider behaviors related to mental disorders and/or address how sexually dimorphic neural processes confer risk or impact resilience for mental disorders. Responsive applications are also required to articulate a strong rationale for how the proposed project will significantly advance our understanding of the etiology and/or underlying pathophysiology of mental disorders. The NIMH will decline applications that are not considered central to the NIMH mission and research priorities. Applications that focus on reproductive behaviors, aggression outside of the context of serious mental illness, or primary sensorimotor processing will not be considered responsive to this announcement. Applicants are strongly encouraged to consult the appropriate program official, listed in Section VII, to discuss the relevance of their proposed work to the NIMH mission as well as to ensure that proposed studies do not duplicate projects currently supported.
Although a formal data sharing plan is not required for applications submitted in response to this FOA, applicants are strongly encouraged to consider and should address data sharing in the application. Data collection, data description, and management procedures should be designed and piloted with future data sharing in mind (e.g., development of a data dictionary, data quality assurance procedures, and/or inclusion of relevant language in consent forms to allow future data sharing where appropriate).
Cahill, L. (2010). Sex influences on brain and emotional memory: the burden of proof has shifted. Prog Brain Res, 186, 29-40).
Nature (2010). Putting Gender on the Agenda, 465, 665.
Office of Research on Women’s Health (2010). Strategic Plan for 2020, Vol II, 27-32 and 237-241.
Application Types Allowed
Revision R01 applications from investigators with active
R01 research project awards issued by NIMH
The OER Glossary and the SF 424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards
The NIMH and ORWH intend to commit approximately $3,700,000 in FY 2013 to fund up to 10 grants in response to this FOA and the companion announcements.
Application budgets are not limited, but need to reflect actual needs of the proposed project. Applicants must submit a budget using the same budget format as was used for the parent award.
Award Project Period
The total project period for an application submitted in response to this FOA may not exceed two years. Applicants may request support for up to 2 years, not to exceed the remaining number of years on the parent grant.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the following
All Program Director(s)/Principal Investigator(s) (PD(s)/PI(s))
must also work with their institutional officials to register with the eRA Commons
or ensure their existing eRA Commons account is affiliated with the eRA Commons
account of the applicant organization.
All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least 4-6 weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always encouraged
to apply for NIH support.
For institutions/organizations proposing multiple PD(s)/PI(s), visit the Multiple Program Director(s)/Principal Investigator(s) Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
To be eligible, the “parent” award on which the revision application is based must be an active NIMH R01 at the time the revision application is submitted. The project period of the revision application may not extend beyond that of the parent award. If a no-cost extension is needed to complete the work to be proposed in the revision, the no-cost extension must be in place before the application is submitted.
For all revision applications, the Project Director(s)/Principal Investigator(s) (PD(s)/PI(s)) must be the same as the PD(s)/PI(s) on the parent award. For revision applications to multiple PD(S)/PI(s) parent awards, the Contact PD(s)/PI(s) must be the PD(s)/PI(s) listed on the parent award. A revision application does not allow a change in the Multiple PD(s)/PI(s) team nor a conversion from a single PD/PI to multiple PD(s)/PI(s).
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Stacia Friedman-Hill, PhD
Division of Developmental Translational Research
National Institute of Mental Health
6001 Executive Boulevard, Room 6180, MSC 9617
Bethesda, MD 20892-9617
Rockville, MD 20852 (for express/courier service)
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
The Research Strategy section should describe concrete indicators of progress toward the research project objectives. These can include specific and feasible measures of progress, potential data sources, and a timeline for major milestones. The measures included should assess the scientific accomplishments, both yearly and overall, of the research project. This should be included within the page limit of the Research Strategy. Progress indicators should be included in each annual progress report and as part of the final report of the grant.
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the SF424 (R&R) Application Guide.
Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Foreign (non-US) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the Central Contractor Registration (CCR). Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by NIMH, NIH. Applications that are incomplete and/or nonresponsive will not be reviewed.
In order to expedite review, applicants are requested to notify the NIMH Referral Office by email at email@example.com when the application has been submitted. Please include the FOA number and title, PD(s)/PI(s) name, and title of the application.
Applications should include a 1 page Introduction that describes the nature of the revision and how it will influence the specific aims, research design, and methods of the parent grant. .
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the study focus on neurobiological systems relevant to human mental disorders? Does the research project further the understanding of the neural mechanisms by which sex differences confer risk for or influence on resilience to mental illnesses? Will the research project lead to greater understanding of how interactions among sex chromosomes, steroid hormones, and environment shape sexually dimorphic neural pathways and behavior? Will the research project lead to identification/clarification of sexually-dimorphic points of vulnerability and developmental divergence? Does the research project address how sex differences in neurodevelopment confer vulnerability or protection in individuals at familial/genetic risk for mental disorders? Will this research facilitate improved understanding of how sexual dimorphisms influence the age of onset and clinical symptoms of mental disorders? Will the research project lay the foundation for future research to improve personalized prevention and interventions?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD(s)/PI(s), do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the application develop or test novel technologies that will facilitate the measurement or analysis of sex specific neural mechanisms such as techniques for visualization and manipulation of in vivo cellular function; novel methods for in vivo examination of epigenetic influences, especially in human brain tissue; new molecular and genetic approaches to study the effect of developmental stage, experience, and hormones?
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Does the study have sufficient power to test hypotheses regarding sex differences? Does the study include both male and female subjects (humans or animals)? Is the evaluation plan well-defined, including (1) specific and feasible measures of progress, (2) adequate and available data sources, and (3) a timeline for major milestones?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NIMH, in accordance with NIH peer review policy and procedures, using the stated review criteria. Review assignments will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Mental Health Council. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD(s)/PI(s) will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Stacia Friedman-Hill, Ph.D
Division of Developmental Translational Research
National Institute of Mental Health
6001 Executive Boulevard, Room 6180, MSC 9617
Bethesda, MD 20892-9617
Telephone: (301) 443-8458
Janine Simmons, M.D., Ph.D
Division of Neuroscience and Basic Behavioral Science
National Institute of Mental Health
6001 Executive Boulevard, Room 7203, MSC 9645
Bethesda, MD 20892-9645
Telephone: (301) 443-1576
Lisa Begg, Dr.P.H., R.N.
Office of Research on Women's Health
National Institutes of Health
6707 Democracy Boulevard, Suite 400, MSC 5484
Bethesda, MD 20817
Telephone: (301) 496-7853
FAX: (301) 402-1798
David Armstrong, Ph.D.
Division of Extramural Activities
National Institute of Mental Health
6001 Executive Boulevard, Room 6138, MSC 9606
Bethesda, MD 20892-9606
Telephone: (301) 443-3534
Rebecca Claycamp, MS, CRA
Division of Extramural Activities
National Institute of Mental Health
6001 Executive Boulevard, Room 6115, MSC 9605
Bethesda, MD 20892-9605
Telephone: (301) 443-2811
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®